Mabwell(SH:688062) Xin Lang Cai Jing·2025-08-13 01:29Group 1 - The core viewpoint of the news highlights the financial performance and trading activities of Maiwei Biotech, indicating a decline in revenue and net profit while showing significant trading volume and high financing levels [1][2] Group 2 - On August 12, Maiwei Biotech's stock fell by 2.10%, with a trading volume of 427 million yuan, and a net financing purchase of 7.34 million yuan, indicating active trading despite the decline [1] - As of August 12, the total margin balance for Maiwei Biotech was 521 million yuan, accounting for 7.70% of its market capitalization, which is above the 90th percentile of the past year [1] - The company reported a revenue of 44.79 million yuan for the first quarter of 2025, a year-on-year decrease of 33.70%, and a net profit loss of 292 million yuan, down 41.85% year-on-year [2] - As of March 31, 2025, the number of shareholders increased by 4.22% to 16,100, while the average circulating shares per person decreased by 4.04% [2] - The main business revenue composition of Maiwei Biotech includes 72.38% from antibody drugs and 27.55% from technical services [1]